Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/24009
Authors: 
Heneric, Oliver
Engel, Dirk
Champenois, Claire
Year of Publication: 
2004
Series/Report no.: 
ZEW Discussion Papers 04-09
Abstract: 
The goal of this paper is to point out the role played by private equity investors (venture-capital companies and corporate investors) in the emergence of a new biotechnology industry in Germany in the second half of the 90?s. This analysis takes into account the different business models and business fields to be found in the biotechnology industry. Based on theoretical arguments, a great relevance of VC-companies in financing young innovative biotechnology firms developing health care applications and technology platforms is expected, whereas corporate investors like pharmaceutical and chemical industries should play a more important role in financing supplier companies. Corporate investors are also expected to be significantly present in the equity financing of health care biotechnology companies. Empirical results from descriptive and multivariate analyses confirm all hypotheses but one: surprisingly, corporate investors invested only marginally in the equity funding of biotechnology firms developing new health care products or services.
Subjects: 
Start-ups
Biotechnology
Venture Capital
Discrete Choice
JEL: 
L6
L21
G32
Document Type: 
Working Paper

Files in This Item:
File
Size
207.97 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.